Chimeric Therapeutics (CHM: $0.039) has announced a capital raise for up to $6.3 million, which comprises of a $1.04 million placement to board and management and a $5.25 million SPP.

Anteris Technologies (AVR: $23.00) finished the March quarter with $32 million in cash following a $35 million capital raise in the quarter at $24 per share. The company's net cash outflow for the last three quarters from operational and investment activities was $14.5 million.

Eli Lilly has achieved unequivocally positive efficacy outcomes from its Phase III study with the drug candidate donanemab for the treatment of early stage Alzheimer's disease. It's the second positive late stage study result in the last year, with Eisai & Co achieving similarly positive results with its drug Leqembi (lecanemab).

Pharmaxis (PXS: $0.061) CEO Gary Phillips said the company is approaching a point when it is about to realise the benefits from the investment that has been made in its clinical programs, with the results from two clinical trials forthcoming. Phillips said it has taken several years to get to this point.

Immuron's (IMC: $0.078) business was severely impacted by the pandemic, with its lead product, Travelan, sold to prevent traveller's diarrhea. Sales fell from $2.7 million in FY2020 to just $166,000 in FY2021.

Imugene (IMU: $0.15) has in-licensed three core technologies. The first and the one on which the company was founded was HER-Vaxx (2013). This technology stimulates the body to develop antibodies against HER2, which is present on breast and gastric tumours in specific patients (who are HER2 positive).

Imricor (IMR: $0.29) is seeking to introduce a new standard-of-care in cardiac ablation procedures. That involves using MRI rather than x-ray to guide the procedures which arguably provides better real-time, functional information on how best to correct irregular heart function.

Chimeric Therapeutics (CHM: $0.076) is commercialising cell therapy technologies sourced from three US research institutions to treat a range of poorly addressed cancers. Patients with these diseases had a five-year survival expectation of just 5% - 27%.

Anteris Technologies (AVR: $21.50) is commercialising the DurAVR aortic heart valve which is implanted by catheter rather than open chest surgery. It is seeking to launch its product in coming years in a market estimated to be worth US$10 billion in 2028, based on only a 15%-20% penetration base of the current patients, according to CEO Wayne Paterson.

Aroa Biosurgery (ARX: $1.08) describes itself as a high growth tissue regeneration company. That high growth has been achieved in FY2023 (its financial year ends 31 March) with annual sales expected to reach the target NZ$60 - NZ$62 million, up at least 54% on the previous year.